Increased sensitivity to cisplatin by nm23-transfected tumor cell lines

Cancer Research

Volumn 56, Issue 13, 1996, Pages 2931-2935

  Ferguson, Amy W ^a,c   Flatow, Ursula ^a   MacDonald, Nicholas J ^a   Larminat, Florence ^b   Bohr, Villhelm A ^b   Steeg, Patricia S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN;

ANIMAL CELL; ARTICLE; BREAST CANCER; CELL PROLIFERATION; CONTROLLED STUDY; CROSS LINKING; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC TRANSFECTION; LUNG METASTASIS; MELANOMA; METASTASIS; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BREAST NEOPLASMS; CELL DIVISION; CISPLATIN; CROSS-LINKING REAGENTS; DNA DAMAGE; DNA, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MELANOMA; MICE; MONOMERIC GTP-BINDING PROTEINS; NEOPLASM PROTEINS; NEOPLASMS; NUCLEOSIDE-DIPHOSPHATE KINASE; OVARIAN NEOPLASMS; TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0029950643     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Steeg, P. S., Bevilacqua, G., Kopper, L., Thorgeirsson, U. P., Talmadge, J. E., Liotta, L. A. and Sobel, M. E. Evidence for a novel gene associated with low tumor metastatic potential. J. Natl. Cancer Inst., 80: 200-204, 1988.
2. Barnes, R , Masood, S., Barker, E , Rosengard, A. M., Coggin, D. L., Crowell, T., King, C. R , Porter-Jordan, K., Wargotz, E. S , Liotta, L. A., and Steeg, P. S. Low Nm23 protein expression in infiltrating ductal breast carcinomas correlates with reduced patient survival. Am. J. Pathol., 139: 245-250, 1991
3. Bevilacqua, G., Sobel, M E., Liotta, L A , and Steeg, P S. Association of low nm23 RNA levels in human primary infiltrating ductal breast carcinomas with lymph node involvement and other histopathological indicators of high metastatic potential. Cancer Res., 49: 5185-5190, 1989.
4. Cropp, C , Lidereau, R., Leone, A , Liscia, D., Cappa, A , Campbell, G., Barker, E., Doussal, V. L , Steeg, P , and Callahan, R. NME1 protein expression and loss of heterozygosity mutations in primary human breast tumors. J. Natl. Cancer Inst , 86: 1167-1169, 1994.
5. Hennessy, C., Henry, J., May, F E. B , Westly, B , Angus, B , and Lennard, T. W. J Expression of the antimetastatic gene nm23 in human breast cancer: An association with good prognosis. J. Natl. Cancer Inst , 83: 281-285, 1991
6. Royds, J A , Stephenson, T. J., Rees, R C., Shorthouse, A. J., and Silcocks, P B. Nm23 product expression in in situ and invasive human breast cancer J. Natl Cancer Inst., 85: 727-731, 1993.
7. Tokunaga, Y., Urano, T., Furakawa, K., Kondo, H., Kanematsu, T., and Shiku, H Reduced expression of Nm23-H1, but not of Nm23-H2, is concordant with the frequency of lymph-node metastasis of human breast cancer Int. J. Cancer, 55: 66-71, 1993.
8. Hirayama, R., Sawai, S., Takagi, Y., Mishima, Y., Kimura, N., Shimada, N., Esaki, Y., Kurashima, C., Utsuyama, M., and Hirokawa, K. Positive relationship between expression of anti-metastatic factor (nm23 gene product or nucleoside diphosphate kinase) and good prognosis in human breast cancer. J Natl. Cancer Inst., 83: 1249-1250, 1991.
9. DeLaRosa, A., Williams, R. L , and Steeg, P. S. Nm23/nucleoside diphosphate kinases: toward a structural and biochemical understanding of its biological functions. Bioessays, 17: 53-62, 1995.
10. Leone, A., Flatow, U., King, C. R., Sandeen, M. A., Margulies, I. M. K., Liotta, L. A., and Steeg, P. S. Reduced tumor incidence, metastatic potential, and cytokine responsiveness of nm25-transfected melanoma cells. Cell, 65: 25-35, 1991.
11. Leone, A., Flatow, U., VanHoutte, K., and Steeg, P. S. Transfection of human nm23-H1 into the human MDA-MB-435 breast carcinoma cell line: effects on tumor metastatic potential, colonization, and enzymatic activity Oncogene, 8: 2325-2333, 1993.
12. Baba, H., Urano, T , Okada, K., Furukawa, K., Nakayama, E., Tanaka, H., Iwasaki, K., and Shiku, H. Two isotypes of murine nm23/nucleoside diphosphate kinse, nm23-M1 and rm23-M2, are involved in metastatic suppression of a murine melanoma line. Cancer Res., 55: 1977-1981, 1995.
13. Parhar, R. S , Shi, Y., Zou, M., Farid, N. R., Ernst, P., and Al-Sedairy, S. Effects of cytokine mediated modulation of Nm23 expression on the invasion and metastatic behavior of B16F10 melanoma cells Int. J Cancer, 60: 204-210, 1995.
14. Fukuda, M., Ishii, A , Yasutomo, Y., Shimada, N , Ishikawa, N , Hanai, N., Nagata, N., Irimura, T., Nicolson, G., and Kimura, N Decreased expression of nucleoside diphosphate kinase a isoform, an nm23-H2 gene homolog, is associated with metastatic potential of rat mammary adenocarcinoma cells. Int. J. Cancer, 65: 531-537, 1996
15. Kantor, J. D., McCormick, B., Steeg, P. S., and Zetter, B. R. Inhibition of cell motility after nm23 transfection of human and murine tumor cells. Cancer Res., 53: 1971-1973, 1993.
16. Hewlett, A. R., Petersen, O. W., Steeg, P. S , and Bissell, M. J. A novel function for Nm23: overexpression in human breast carcinoma cells leads to the formation of basement membrane and growth arrest. J. Natl. Cancer Inst., 86: 1838-1844, 1994.
17. Larminat, F., Zhen, W., and Bohr, V. Gene-specific DNA repair of interstrand cross-links induced by chemotherapeutic agents can be preferential. J. Biol. Chem., 268: 2649-2654, 1993
18. Vos, J., and Hanawalt, P. Processing of psoralen adducts in an active human gene: repair and replication of DNA containing monoadducts and iterstrand cross-links. Cell, 50: 789-799, 1987.
19. Zhen, W., Link, C. J., Jr., O'Connor, P., Reed, E., Parker, R., Howell, S., and Bohr, V. Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol. Cell. Biol., 12: 3689-3698, 1992.
20. Bohr, V. Gene-specific damage and repair of DNA adducts and cross links. IARC Sci. Publ. 125: 361-369, 1994.
21. Bohr, V. DNA repair fine structure and its relations to genomic instability Carcinogenesis, 16: 2885-2892, 1995.
22. Bookman, M., and Ozols, R. Factoring outcomes in ovarian cancer. J. Clin. Oncol., 14: 325-327, 1996
23. Scambia, G , Ferrandina, G., Marone, M , Panici, P. B., Giannitelli, C., Piantelli, M., Leone, A., and Manusco, S. Nm23 in ovarian cancer: correlation with clinical outcome and other clinico-pathological and biochemical prognostic markers. J. Clin. Oncol., 14: 334-342, 1996.
24. Frisch, S., and Dolter, K. Adenovirus E1a-mediated tumor suppression by a c-erbB-2/neu independent mechanism. Cancer Res., 55: 5551-5555, 1995.
25. Dickstein, B., Wosikowski, K., and Bates, S. Increased resistance to cytotoxic agents in ZR75B human breast cancer cells transfected with epidermal growth factor receptor. Mol. Cell Endocrinol , 110 205-211, 1995
26. Fan, Z., Baselga, J., Masui, H., and Mendelsohn, J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts Cancer Res., 53: 4637-4642, 1993.
27. Benz, C., Scott, G., Sarup, J., Johnson, R., Tripathy, D., Coronado, E., Shepard, H., and Osborne, C. Estrogen-dependent, tamoxifen resistant tumorigenic growth of MCF-7 cells transfected with HER-2/neu. Breast Cancer Res Treat., 24: 85-95, 1993.
28. Pietras, R., Fendly, B., Chazin, V., Pegram, M , Howell, S., and Slamon, D. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene, 9: 1829-1838, 1994.
29. Fan, S., Smith, M. L., Rivet, D. J , II, Duba, D , Zhan, Q , Kohn, K. W , Fornace, A. F., Jr., and O'Connor, P. M. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res., 55: 1649-1654, 1995.